Palvella Therapeutics’ (PVLA) Buy Rating Reaffirmed at BTIG Research

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a report issued on Thursday,Benzinga reports. They presently have a $192.00 target price on the stock. BTIG Research’s target price would indicate a potential upside of 143.93% from the stock’s previous close.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus boosted their price target on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, November 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Canaccord Genuity Group upped their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. HC Wainwright set a $200.00 price target on shares of Palvella Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Truist Financial boosted their price objective on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and an average target price of $158.69.

Palvella Therapeutics Trading Down 6.3%

NASDAQ:PVLA opened at $78.71 on Thursday. The firm has a 50-day moving average price of $97.13 and a two-hundred day moving average price of $71.89. Palvella Therapeutics has a twelve month low of $12.48 and a twelve month high of $114.69. The company has a market capitalization of $931.93 million, a P/E ratio of -29.93 and a beta of -0.16.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities research analysts predict that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 12,906 shares of company stock valued at $1,205,980 over the last 90 days. 20.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds have recently made changes to their positions in PVLA. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics during the third quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics during the second quarter worth about $37,000. JPMorgan Chase & Co. increased its stake in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $85,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.